3B Blackbio Dx Limited Share Price & Analysis
₹1,272.1▲ +0.37%Updated 21 Jul 2026, 05:01 pm IST
LTP
₹1,272.1
+0.37%
Open
₹—
High
₹1,290
Low
₹1,224
Close
₹1,272.1
52W High
₹1,750
52W Low
₹1,084
Volume
12K
Lot Size
1
Sector
Healthcare
Market Cap
₹1K Cr
Face Value
₹10
Small Cap
Price Chart
Fundamentals
P/E
18.3
Sector P/E
54.4
P/B
3.37
EPS
₹66.92
ROE
19.8%
ROCE
25.5%
D/E Ratio
0.01
Div Yield
0.32%
Book Value
₹378
+
Strengths
- ✓Strong return on equity (ROE 19.8%)
- ✓Efficient capital deployment (ROCE 25.5%)
- ✓Attractively valued vs sector (P/E 18.3x vs industry 54.4x)
- ✓Virtually debt-free
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
3BBLACKBIO · as of Mar 2026
Promoters41.28%
FII2.49%▼0.19
DII1.60%▼0.14
Public54.64%▲0.35
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 38.43% | 41.29% | 41.28% | 41.28% | 41.28% | 41.28% |
| FII | 3.38% | 2.97% | 3.28% | 3.27% | 2.68% | 2.49% |
| DII | 1.18% | 1.89% | 1.96% | 1.96% | 1.74% | 1.60% |
| Public | 56.99% | 53.85% | 53.48% | 53.48% | 54.29% | 54.64% |
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹50.35 Cr ▲48.5% | ₹33.9 Cr ▲52.5% | ₹22.23 Cr ▼1.2% | ₹22.5 Cr ▼11.4% | ₹25.39 Cr ▼12.9% | ₹29.15 Cr ▲50.0% | ₹19.43 Cr ▼15.5% | ₹23 Cr |
| Op. Profit | ₹21.72 Cr ▲47.5% | ₹14.73 Cr ▲24.5% | ₹11.83 Cr ▲49.4% | ₹7.92 Cr ▼47.4% | ₹15.07 Cr ▼6.8% | ₹16.17 Cr ▲47.7% | ₹10.95 Cr ▲9.5% | ₹10 Cr |
| OPM | 43.1% ▼0.7% | 43.5% ▼18.4% | 53.2% ▲51.2% | 35.2% ▼40.7% | 59.4% ▲7.0% | 55.5% ▼1.6% | 56.4% ▲31.1% | 43.0% |
| Net Profit | ₹22.44 Cr ▲49.2% | ₹15.04 Cr ▲18.9% | ₹12.65 Cr ▲57.3% | ₹8.04 Cr ▼40.4% | ₹13.49 Cr ▼9.3% | ₹14.87 Cr ▲31.6% | ₹11.3 Cr ▲25.6% | ₹9 Cr |
| EPS (₹) | 25.32 ▲47.7% | 17.14 ▲16.8% | 14.67 ▲49.8% | 9.79 ▼37.3% | 15.61 ▼8.6% | 17.07 ▲31.6% | 12.97 ▲25.6% | 10.33 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹142 Cr ▲47.9% | ₹96 Cr ▲29.7% | ₹74 Cr ▲19.4% | ₹62 Cr ▼23.5% | ₹81 Cr ▼64.3% | ₹227 Cr ▲682.8% | ₹29 Cr ▲26.1% | ₹23 Cr ▲0.0% | ₹23 Cr ▲43.8% | ₹16 Cr |
| Expenses | ₹85 Cr ▲84.8% | ₹46 Cr ▲12.2% | ₹41 Cr ▲24.2% | ₹33 Cr ▼25.0% | ₹44 Cr ▼42.9% | ₹77 Cr ▲285.0% | ₹20 Cr ▲25.0% | ₹16 Cr ▼11.1% | ₹18 Cr ▲28.6% | ₹14 Cr |
| Op. Profit | ₹57 Cr ▲14.0% | ₹50 Cr ▲51.5% | ₹33 Cr ▲13.8% | ₹29 Cr ▼21.6% | ₹37 Cr ▼75.3% | ₹150 Cr ▲1566.7% | ₹9 Cr ▲28.6% | ₹7 Cr ▲40.0% | ₹5 Cr ▲66.7% | ₹3 Cr |
| OPM | 40.0% ▼23.1% | 52.0% ▲18.2% | 44.0% ▼6.4% | 47.0% ▲2.2% | 46.0% ▼30.3% | 66.0% ▲106.3% | 32.0% ▲3.2% | 31.0% ▲34.8% | 23.0% ▲43.8% | 16.0% |
| Other Income | ₹26 Cr ▲73.3% | ₹15 Cr ▲15.4% | ₹13 Cr ▲85.7% | ₹7 Cr ▲0.0% | ₹7 Cr ▲133.3% | ₹3 Cr ▲50.0% | ₹2 Cr ▲100.0% | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr ▼100.0% | ₹1 Cr ▲0.0% | ₹1 Cr |
| Depreciation | ₹5 Cr ▲400.0% | ₹1 Cr ▲0.0% | ₹1 Cr ▲0.0% | ₹1 Cr ▲0.0% | ₹1 Cr ▲0.0% | ₹1 Cr ▲0.0% | ₹1 Cr ▲0.0% | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| PBT | ₹77 Cr ▲20.3% | ₹64 Cr ▲45.5% | ₹44 Cr ▲25.7% | ₹35 Cr ▼18.6% | ₹43 Cr ▼71.7% | ₹152 Cr ▲1420.0% | ₹10 Cr ▲42.9% | ₹7 Cr ▲40.0% | ₹5 Cr ▲400.0% | ₹1 Cr |
| Tax % | 22.0% ▼12.0% | 25.0% ▼10.7% | 28.0% ▲3.7% | 27.0% ▲3.8% | 26.0% ▲4.0% | 25.0% ▲8.7% | 23.0% ▼8.0% | 25.0% ▲4.2% | 24.0% ▲26.3% | 19.0% |
| Net Profit | ₹60 Cr ▲25.0% | ₹48 Cr ▲50.0% | ₹32 Cr ▲23.1% | ₹26 Cr ▼18.8% | ₹32 Cr ▼71.9% | ₹114 Cr ▲1325.0% | ₹8 Cr ▲60.0% | ₹5 Cr ▲66.7% | ₹3 Cr ▲200.0% | ₹1 Cr |
| EPS (₹) | 68.27 ▲22.9% | 55.57 ▲48.6% | 37.4 ▲8.2% | 34.55 ▼19.4% | 42.89 ▼71.7% | 151.66 ▲1381.1% | 10.24 ▲25.2% | 8.18 ▲52.9% | 5.35 ▲204.0% | 1.76 |
| Div Payout | 7.0% ▲0.0% | 7.0% ▼12.5% | 8.0% ▲0.0% | 8.0% ▼66.7% | 24.0% ▲300.0% | 6.0% ▼14.3% | 7.0% ▲16.7% | 6.0% ▼33.3% | 9.0% ▼47.1% | 17.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹9 Cr ▲0.0% | ₹9 Cr ▲0.0% | ₹9 Cr ▲0.0% | ₹9 Cr ▲28.6% | ₹7 Cr ▲0.0% | ₹7 Cr ▲0.0% | ₹7 Cr ▲16.7% | ₹6 Cr ▲0.0% | ₹6 Cr ▲0.0% | ₹6 Cr |
| Reserves | ₹290 Cr ▲11.5% | ₹260 Cr ▲21.5% | ₹214 Cr ▲15.7% | ₹185 Cr ▲26.7% | ₹146 Cr ▲16.8% | ₹125 Cr ▲400.0% | ₹25 Cr ▲56.3% | ₹16 Cr ▲33.3% | ₹12 Cr ▲140.0% | ₹5 Cr |
| Borrowings | ₹0 Cr | ₹0 Cr ▼100.0% | ₹1 Cr ▼50.0% | ₹2 Cr ▼33.3% | ₹3 Cr ▲50.0% | ₹2 Cr ▼50.0% | ₹4 Cr ▼33.3% | ₹6 Cr ▲0.0% | ₹6 Cr ▼33.3% | ₹9 Cr |
| Other Liabilities | ₹42 Cr ▲55.6% | ₹27 Cr ▲12.5% | ₹24 Cr ▲26.3% | ₹19 Cr ▼48.6% | ₹37 Cr ▼37.3% | ₹59 Cr ▲555.6% | ₹9 Cr ▲12.5% | ₹8 Cr ▲33.3% | ₹6 Cr ▲0.0% | ₹6 Cr |
| Total Liabilities | ₹341 Cr ▲15.2% | ₹296 Cr ▲19.4% | ₹248 Cr ▲15.9% | ₹214 Cr ▲11.5% | ₹192 Cr ▼1.0% | ₹194 Cr ▲331.1% | ₹45 Cr ▲25.0% | ₹36 Cr ▲20.0% | ₹30 Cr ▲15.4% | ₹26 Cr |
| Assets | ||||||||||
| Fixed Assets | ₹17 Cr ▲142.9% | ₹7 Cr ▲0.0% | ₹7 Cr ▼12.5% | ₹8 Cr ▲14.3% | ₹7 Cr ▲40.0% | ₹5 Cr ▲25.0% | ₹4 Cr ▲0.0% | ₹4 Cr ▲0.0% | ₹4 Cr ▲33.3% | ₹3 Cr |
| CWIP | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹160 Cr ▲2.6% | ₹156 Cr ▲33.3% | ₹117 Cr ▲27.2% | ₹92 Cr ▼1.1% | ₹93 Cr ▲57.6% | ₹59 Cr ▲5800.0% | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹163 Cr ▲23.5% | ₹132 Cr ▲7.3% | ₹123 Cr ▲7.9% | ₹114 Cr ▲22.6% | ₹93 Cr ▼28.5% | ₹130 Cr ▲225.0% | ₹40 Cr ▲25.0% | ₹32 Cr ▲23.1% | ₹26 Cr ▲18.2% | ₹22 Cr |
| Total Assets | ₹341 Cr ▲15.2% | ₹296 Cr ▲19.4% | ₹248 Cr ▲15.9% | ₹214 Cr ▲11.5% | ₹192 Cr ▼1.0% | ₹194 Cr ▲331.1% | ₹45 Cr ▲25.0% | ₹36 Cr ▲20.0% | ₹30 Cr ▲15.4% | ₹26 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹43 Cr ▲59.3% | ₹27 Cr ▲35.0% | ₹20 Cr ▼45.9% | ₹37 Cr ▼62.2% | ₹98 Cr ▲1300.0% | ₹7 Cr ▲75.0% | ₹4 Cr ▲100.0% | ₹2 Cr ▲100.0% | ₹1 Cr ▲0.0% | ₹1 Cr |
| Investing CF | ₹-33 Cr ▼65.0% | ₹-20 Cr ▼233.3% | ₹15 Cr ▲153.6% | ₹-28 Cr ▲60.0% | ₹-70 Cr ▼6900.0% | ₹-1 Cr ▲0.0% | ₹-1 Cr ▲0.0% | ₹-1 Cr | ₹0 Cr | ₹0 Cr |
| Financing CF | ₹-3 Cr ▲25.0% | ₹-4 Cr ▲20.0% | ₹-5 Cr ▲66.7% | ₹-15 Cr ▼650.0% | ₹-2 Cr ▼300.0% | ₹1 Cr ▲200.0% | ₹-1 Cr | ₹0 Cr | ₹0 Cr ▲100.0% | ₹-1 Cr |
| Net Cash Flow | ₹7 Cr ▲133.3% | ₹3 Cr ▼90.0% | ₹30 Cr ▲600.0% | ₹-6 Cr ▼123.1% | ₹26 Cr ▲271.4% | ₹7 Cr ▲250.0% | ₹2 Cr ▲100.0% | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Free Cash Flow | ₹42 Cr ▲61.5% | ₹26 Cr ▲44.4% | ₹18 Cr ▼48.6% | ₹35 Cr ▼63.5% | ₹96 Cr ▲1500.0% | ₹6 Cr ▲100.0% | ₹3 Cr ▲200.0% | ₹1 Cr | ₹0 Cr ▼100.0% | ₹1 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 138d ▼22.9% | 179d ▼10.5% | 200d ▲47.1% | 136d ▲142.9% | 56d ▼77.8% | 252d ▼13.1% | 290d ▲12.0% | 259d ▼19.3% | 321d ▲13.4% | 283d |
| Inventory Days | 124d ▼12.1% | 141d ▼14.0% | 164d | — | — | — | — | — | 175d ▲22.4% | 143d |
| Days Payable | 28d ▼57.6% | 66d ▼4.3% | 69d | — | — | — | — | — | 186d ▼8.4% | 203d |
| Cash Conv. Cycle | 235d ▼7.1% | 253d ▼14.5% | 296d ▲117.6% | 136d ▲142.9% | 56d ▼77.8% | 252d ▼13.1% | 290d ▲12.0% | 259d ▼16.5% | 310d ▲39.0% | 223d |
| Working Capital Days | 169d ▼21.4% | 215d ▼10.8% | 241d ▲48.8% | 162d ▲149.2% | 65d ▼76.4% | 275d ▼4.2% | 287d ▲13.4% | 253d ▲2.4% | 247d ▲20.5% | 205d |
| ROCE | 26.0% ▲23.8% | 21.0% ▲10.5% | 19.0% ▼29.6% | 27.0% ▼83.3% | 162.0% ▲422.6% | 31.0% ▲10.7% | 28.0% ▲16.7% | 24.0% ▲84.6% | 13.0% ▲85.7% | 7.0% |
Source: Screener.in · Lower days = better efficiency
About 3B Blackbio Dx Limited
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
Healthcare · Healthcare Services
Related Analysis
Frequently Asked Questions
What is 3B Blackbio Dx Limited share price today?▾
3B Blackbio Dx Limited (3BBLACKBIO) is currently trading at ₹1,272.1 on NSE, up 0.37% as of the last market session. Prices update daily after market close on MarketNetra.
Is 3B Blackbio Dx Limited available in F&O (Futures & Options)?▾
Yes, 3B Blackbio Dx Limited (3BBLACKBIO) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is 3B Blackbio Dx Limited 52-week high and low?▾
3B Blackbio Dx Limited's 52-week high is ₹1,750 and the 52-week low is ₹1,084. The current price of ₹1,272.1 is 27.3% below the 52W high.
What is 3B Blackbio Dx Limited P/E ratio?▾
3B Blackbio Dx Limited's current P/E ratio is 18.3. This indicates the market is paying ₹18.3 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade 3B Blackbio Dx Limited options?▾
3B Blackbio Dx Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade 3BBLACKBIO options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.